Safety evaluation of mass inoculation of 23 valent pneumococcal polysaccharide vaccine among elderly people aged 60 and above in Shanghai from 2013 to 2017
10.3760/cma.j.cn112150-20191011-00779
- VernacularTitle:2013—2017年上海市60岁及以上老年人群大规模接种23价肺炎球菌多糖疫苗的安全性评价
- Author:
Xiang GUO
1
;
Jing QIU
;
Jia REN
;
Jiechen LIU
;
Xiaodong SUN
Author Information
1. 上海市疾病预防控制中心免疫规划所 200336
- Keywords:
Aged;
23 valent pneumococcal polysaccharide vaccine;
Safety evaluation;
Surveillance
- From:
Chinese Journal of Preventive Medicine
2020;54(9):929-933
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the safety of 23 Valent Pneumococcal Polysaccharide Vaccine (PPV23) among eldly people aged 60 and above in Shanghai.Methods:A total of 1 310 660 monitoring data of adverse events following immunization (AEFI) of PPV23 among people aged 60 and above were collected through the National AEFI Surveillance System from September 14, 2013 to December 31, 2017 in Shanghai. And the descriptive epidemiological methods were used for analysis.Results:433 cases of AEFI were reported from September 14, 2013 to December 31, 2017, with the incidence rate of AEFI was 33.04/100 000 doses. The general reactions were reported as 392 cases (90.53%), with 17 cases of abnormal reactions (3.93%), 23 cases of coincidences (5.31%) and 1 case of psychogenic reactions (0.23%). The reported incidence rates of general reactions and abnormal reactions of free PPV23 inoculation among elderly people in urban areas were 41.31 per 100 000 doses and 1.91/100 000 doses, respectively, which were higher than those in suburban areas (24.18/100 000 doses, 1.32/100 000 doses) and exurban areas (27.84/100 000 doses, 0.59/100 000 doses). The reported incidence rate of general reaction in females (35.38/100 000 doses) was higher than that in males (24.06/100 000 doses), and the reported incidence rate of abnormal reaction in males (1.58/100 000 doses) was higher than that in females (1.03/100 000 doses). The reported incidence rates of general and abnormal reactions were the highest in 60-64 years old group (62.65/100 000 doses and 4.87/100 000 doses, respectively). In addition, all patients with general reactions or abnormal reactions were better or cured.Conclusion:PPV23 vaccination is safe among people aged 60 and above in Shanghai.
